Description
Get Access to Lanadelumab for Injection in India
Takhzyro contains the drug lanadelumab-flyo, which is a biologic medication. It is a plasma kallikrein inhibitor (monoclonal antibody) used for prophylaxis to treat or prevent attacks of types I and II hereditary angioedema (HAE) in patients aged 12 years and older.
It is not known if takhzyro injection is safe and effective in children aged under 12 years.
Takhzyro; a preventive treatment you take just once every two weeks; comes as Injection: 300 mg/2 mL (150 mg/mL) solution, single-dose, ready-to-use, prefilled syringe.
The recommended dose is 300 mg every two weeks for patients starting on Takhzyro. If patients have zero attacks for more than six months, their health specialist may consider prescribing Takhzyro 300 mg every four weeks. It is not advisable to attempt to take this injection without first being trained by a health specialist.





